The short answer
No DSIP gene has been isolated, no precursor protein identified and no receptor characterised. Those three findings are how a proposed endogenous peptide normally becomes accepted biology, and DSIP has none of them nearly fifty years after isolation.
Key facts
- Gene
- Not identified
- Precursor protein
- Not characterised
- Receptor
- Not identified
- Time since isolation
- Nearly 50 years
- Consequence
- No mechanism to test; no knockout possible
- Contrast
- MOTS-c, humanin (both gene-located)
How an endogenous peptide normally gets established
There is a recognisable sequence. A peptide is isolated and sequenced. Its gene is located, which explains where it comes from and how its production is regulated. A precursor protein is characterised, showing how it is processed. A receptor is identified, giving a mechanism and a target. At that point the peptide has a place in physiology rather than a suggestive result attached to it.
What DSIP has and has not
It has an isolation, a sequence, a synthesis and a large literature. It does not have a gene, a precursor or a receptor. Each absence is individually surmountable (plenty of molecules waited decades for a receptor), but the combination, sustained across nearly fifty years of active interest, is unusual and is the single most informative fact about the compound.
Research material referenced
DSIP 5mg, third-party HPLC tested
Why a missing receptor is the hardest gap
A receptor is what makes a mechanism testable. With one, you can measure binding, build dose-response relationships, design antagonists and establish whether an observed effect actually runs through the proposed pathway. Without one, an observed effect can only be described, not explained, and cannot be distinguished from action through some entirely different route.
Why a missing gene is the hardest to explain
Modern genomics is very good at finding coding sequences. MOTS-c was located inside the mitochondrial 12S rRNA gene in 2015: a short open reading frame nested inside sequence already annotated as something else, and it was still found. That a putative endogenous peptide first described in 1977 has no identified gene in the genomic era is a substantive observation about its likely status.
What this does not prove
Absence of evidence is not proof of absence. It remains possible that DSIP has an endogenous role yet to be characterised. The honest position is not that DSIP has been refuted but that it has never been established, and that the specific gaps are the ones that would matter most.
How to weigh it against the published literature
When a study reports an effect of administered DSIP, that effect is being produced by a synthetic peptide at an experimentally chosen concentration through an unknown mechanism. That can still be a real and interesting observation. It is not evidence that the compound performs a physiological function, and the two claims should not be reported as one.
Frequently asked questions
Could a DSIP receptor still be found?
Possible. Receptors have been identified decades after their ligands. But sustained failure across nearly fifty years is itself informative.
Does no gene mean DSIP is not endogenous?
It means it has not been established as endogenous. That is a weaker statement than refutation, and a much weaker one than the name implies.
How does this compare with other research peptides?
MOTS-c and humanin both have identified coding sequences in the mitochondrial genome. DSIP has none in any genome, which is the clearest contrast available.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedKovalzon VM, DSIP: a still unresolved riddle. J Neurochem 2006 (PMID 16539679)pubmed.ncbi.nlm.nih.gov
- PubMedSchoenenberger GA et al., Characterization of a delta-EEG (sleep)-inducing peptide. PNAS 1977 (PMID 265572)pubmed.ncbi.nlm.nih.gov
- PubMedLee C et al., The mitochondrial-derived peptide MOTS-c. Cell Metab 2015 (PMID 25738459)pubmed.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More DSIP (Delta Sleep-Inducing Peptide) articles
- What Delta Waves Are, and Why DSIP Is Named for ThemDelta waves are high-amplitude, low-frequency EEG activity below about 4 Hz, characteristic of deep non-REM sleep. What they measure and what they do not.
- DSIP Structure, Sequence and Physical PropertiesDSIP is WAGGDASGE, 9 residues, 848.8 Da, C35H48N10O15. An unusually acidic, glycine-rich sequence with a single aromatic residue and no cysteine.
- DSIP CAS Number and Chemical IdentityDSIP CAS is 62568-57-4, PubChem CID 68816, UNII YN28Z5YZ73, and its INN is emideltide. Identifiers for checking a certificate against the literature.
- DSIP Storage, Stability and ReconstitutionNo cysteine or methionine, so the usual degradation routes do not apply. What a strongly acidic, glycine-rich sequence needs instead.
- DSIP in the Published LiteratureAbout 519 indexed PubMed records across nearly fifty years, and a central claim still unresolved. Why volume of publication is not weight of evidence.